Inamrinone Side Effects
Not all side effects for inamrinone may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to inamrinone: intravenous solution
In addition to its needed effects, some unwanted effects may be caused by inamrinone. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking inamrinone:Less common
- irregular heartbeat
- low blood pressure
- Black, sticky stools
- blood in urine or stools
- burning at site of injection
- chest pain or discomfort
- loss of appetite
- pinpoint red spots on skin
- unusual bleeding or bruising
- weight loss
- yellow eyes or skin
Some of the side effects that can occur with inamrinone may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:Less common
- nausea or vomiting
- stomach pain
For Healthcare Professionals
Applies to inamrinone: intravenous solution
A potentially serious hematologic abnormality is thrombocytopenia. Reduced platelet counts have been seen in 20% to 46% of patients, but were rarely symptomatic. Thrombocytopenia appears to be related to the total daily dose and duration of infusion and generally has resolved within 2 to 4 days following amrinone withdrawal.
Rare cases of hemorrhagic pericardial effusions and splenomegaly have been associated with inamrinone-induced thrombocytopenia.
Thrombocytopenia may not necessitate drug discontinuation. It is recommended that patients whose platelet count is less than 150,000/mm3 be carefully monitored.
There is limited evidence to support either a direct drug-associated platelet effect or platelet destruction due to an IgG antiplatelet antibody. The exact mechanism is not known.
Cardiovascular side effects have included hypotension, arrhythmias, and heart failure. Infusion-related hypotension occurred in 1% to 3% of patients. New cases of sustained atrial and ventricular arrhythmias or worsened congestive heart failure have been reported in 9% of patients. Some data are from uncontrolled studies and a casual relationship may be difficult to determine due to the serious underlying cardiac disease of the study population. Chest pain is reported in 0.2% of patients.
Gastrointestinal symptoms of general abdominal pain, anorexia, diarrhea, nausea, or vomiting have occurred in up to 27% of patients. Rare complaints of smell or taste loss have been reported.
Nervous system side effects have included dizziness, headache, lightheadedness, or paresthesias in approximately 20% of patients. Somnolence and fatigue are reported in 3% and 15% of patients, respectively.
Dermatologic side effects have included skin dryness and yellow nail discoloration.
Hepatic toxicity has been reported after long-term oral use of inamrinone. In a study of 173 patients, approximately 20% developed elevated serum SGOT or LDH levels. Hepatotoxicity associated with short-term intravenous use has occurred rarely. Elevations in bilirubin and jaundice have been reported.
Cases of reproducible and reversible hepatitis have been associated with inamrinone use. In some cases, elevated serum transaminases and LDH were accompanied by bilateral pulmonary infiltrates and eosinophilia suggestive of an allergic drug reaction.
Hypersensitivity to amrinone may present as a generalized viral-like syndrome characterized by myalgias, arthralgias, and fever. This syndrome may be accompanied by myositis, diffuse pulmonary infiltrates, pruritus, and confusion.
Respiratory infections have been reported in up to 22% of patients.
Local intravenous site injection pain has been reported in 0.2% of patients. This may be minimized by diluting the inamrinone infusate in normal or half-normal saline to a final concentration of 1 to 3 mg/mL.
More about inamrinone
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.